PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer

Dual Faces of IFN  in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

(2016) M. Mandai et al.   CLINICAL CANCER RESEARCH

Regulatory T cells and potential inmmunotherapeutic targets in lung cancer

(2015) Ding Zhang et al.   CANCER AND METASTASIS REVIEWS

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumorassoziierte Makrophagen

(2015) G. Niedobitek et al.   PATHOLOGE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells

(2015) Hongzhong Li et al.   Oncotarget

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

(2015) Xinbing Sui et al.   Oncotarget

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

(2015) Lars Henning Schmidt et al.   PLoS One

PD-L1 expression and tumor-infiltrating lymphocytes

(2014) Kurt A Schalper   OncoImmunology

The role of tumor-associated macrophages in breast cancer progression

(2013) ELIAS OBEID et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Dynamic Interplay of Oncogenes and T Cells Induces PD-L1 in the Tumor Microenvironment

(2013) A. J. Rech et al.   Cancer Discovery

Augmented Macrophage Differentiation and Polarization of Tumor-associated Macrophages Towards M1 Subtype in Listeria-administered Tumor-bearing Host

(2012) Rakesh K. Rai et al.   JOURNAL OF IMMUNOTHERAPY

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The Two Faces of Interferon-  in Cancer

(2011) M. R. Zaidi et al.   CLINICAL CANCER RESEARCH

M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells

(2011) M. Heusinkveld et al.   JOURNAL OF IMMUNOLOGY

The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo

(2011) A. M. Paterson et al.   JOURNAL OF IMMUNOLOGY

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics

(2010) Yael S. Barach et al.   TRENDS IN MOLECULAR MEDICINE

IFN  Promotes Papilloma Development by Up-regulating Th17-Associated Inflammation

(2009) M. Xiao et al.   CANCER RESEARCH

Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer

(2009) S. Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

(2008) David S. Alberts et al.   GYNECOLOGIC ONCOLOGY

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape

(2008) Jessica B. Katz et al.   IMMUNOLOGICAL REVIEWS

Immune escape as a fundamental trait of cancer: focus on IDO

(2008) G C Prendergast   ONCOGENE